// App-Quantinova.ai

AB0827 : IMPACT OF BASELINE BODY MASS INDEX ON THE EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS

Researchers

Presenter

  • C. T. Ritchlin

Principal Investigators

  • A. Ogdie

  • J. T. Giles

  • J. J. Gomez-Reino

  • P. Helliwell

  • L. Stockert

  • P. Young

  • W. Joseph

  • R. Mundayat

  • D. Graham

  • J. Woolcott

  • A. B. Romero

Medical Centers

  • University of Rochester Medical Center, Rochester, United States of America

  • University of Pennsylvania, Philadelphia, United States of America

  • Columbia University - New York - United States of America

  • Hospital Clinico Universitario, Santiago De Compostela, Spain

  • University of Leeds, Leeds, United Kingdom

  • Pfizer Inc., Collegeville, United States

  • Pfizer, Inc, Groton, CT, United States of America

  • Pfizer Inc, Barcelona, Spain

Locations

  • United States

  • Spain

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

Biomarkers

  • Fibrillin-1

  • Tumor necrosis factor

  • Body mass index

Drug/Treatment

  • Tasocitinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT01877668]

  • NCT01882439]

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved